Author: Yu, Jia; Yuan, Xuan; Chen, Hang; Chaturvedi, Shruti; Braunstein, Evan M.; Brodsky, Robert A.
Title: Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition Cord-id: 900hj9ta Document date: 2020_10_29
ID: 900hj9ta
Snippet: Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious respiratory virus that can lead to venous/arterial thrombosis, stroke, renal failure, myocardial infarction, thrombocytopenia, and other end-organ damage. Animal models demonstrating end-organ protection in C3-deficient mice and evidence of complement activation in humans have led to the hypothesis that SARS-CoV-2 triggers complement-mediated endothelial damage, but the mechanism is unclear. Here, we dem
Document: Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious respiratory virus that can lead to venous/arterial thrombosis, stroke, renal failure, myocardial infarction, thrombocytopenia, and other end-organ damage. Animal models demonstrating end-organ protection in C3-deficient mice and evidence of complement activation in humans have led to the hypothesis that SARS-CoV-2 triggers complement-mediated endothelial damage, but the mechanism is unclear. Here, we demonstrate that the SARS-CoV-2 spike protein (subunit 1 and 2), but not the N protein, directly activates the alternative pathway of complement (APC). Complement-dependent killing using the modified Ham test is blocked by either C5 or factor D inhibition. C3 fragments and C5b-9 are deposited on TF1PIGAnull target cells, and complement factor Bb is increased in the supernatant from spike protein–treated cells. C5 inhibition prevents the accumulation of C5b-9 on cells, but not C3c; however, factor D inhibition prevents both C3c and C5b-9 accumulation. Addition of factor H mitigates the complement attack. In conclusion, SARS-CoV-2 spike proteins convert nonactivator surfaces to activator surfaces by preventing the inactivation of the cell-surface APC convertase. APC activation may explain many of the clinical manifestations (microangiopathy, thrombocytopenia, renal injury, and thrombophilia) of COVID-19 that are also observed in other complement-driven diseases such as atypical hemolytic uremic syndrome and catastrophic antiphospholipid antibody syndrome. C5 inhibition prevents accumulation of C5b-9 in vitro but does not prevent upstream complement activation in response to SARS-CoV-2 spike proteins.
Search related documents:
Co phrase search for related documents- absence presence and accumulation prevent: 1, 2
- absence presence and active conformation: 1, 2, 3
- absence presence and acute phase: 1, 2, 3, 4, 5, 6, 7, 8
- absence presence and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- absence presence and acute respiratory failure: 1, 2, 3, 4, 5, 6, 7, 8, 9
- absence presence and additional research: 1
- absence presence and liver enzyme: 1, 2, 3
- absence presence and lung microvasculature: 1
- accessory protein and activation level: 1
- accessory protein and activation product: 1
- accessory protein and acute respiratory distress syndrome: 1, 2, 3
- accessory protein and acute respiratory failure: 1
- accumulation prevent and acute respiratory distress syndrome: 1
- activation level and acute phase: 1, 2
- activation level and acute respiratory distress syndrome: 1
- activation product and acute respiratory distress syndrome: 1
- active conformation and acute phase: 1
- active conformation and acute respiratory distress syndrome: 1
- acute phase and low platelet: 1
Co phrase search for related documents, hyperlinks ordered by date